Track topics on Twitter Track topics that are important to you
Amgen and Allergan have won the first U.S. approval for a biosimilar cancer treatment following FDA authorization of their Mvasi™ (bevacizumab-awwb), a near-copy of Roche subsidiary Genentech’s Avastin ® (bevacisumab). Mvasi has been approved for adults with five types of cancer, including in combination with chemotherapy for non-squamous non-small-cell lung cancer (NSCLC), in combination with chemotherapy for metastatic colorectal cancer (mCRC), glioblastoma, metastatic renal cell carcinoma in combination with interferon alfa, and in combination with chemotherapy for persistent, recurrent, or metastatic carcinoma of the cervix. Just when Mvasi will reach the market and how much it will cost patients remain unknown. Avastin retains U.S. patent exclusivity until 2019 and European patent exclusivity until 2022. Those patents have already been at the center of a legal wrangle between Amgen and Genentech earlier this year, and the dispute may flare up again before the first prescription is dispensed. ...NEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...